Table 1.
Baseline characteristics of 48 patients experiencing low-level viremia episodes.
Figure 1.
Resistance-associated mutations to nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI) and integrase inhibitors (INI) before and after the low-level viremia (LLV) period, according to the 2009 International AIDS Society-USA list.
Figure 2.
Resistance to antiretroviral drugs at the onset and the end of the low-level viremia period, assessed using the 2009 ANRS HIV-1 drug-resistance algorithm v18.
LLV: low level viremia, 3TC/FTC: lamivudine/emtricitabine, ZDV: zidovudine, d4T: stavudine, ABC: abacavir, ddI: didanosine, TDF: tenofovir, EFV: efavirenz, NVP: nevirapine, ETV: etravirine, IDV: indinavir, NFV: nelfinavir, TPV: tipranavir, SQV: saquinavir, LPV: lopinavir, ATV: atazanavir, FPV: fosamprenavir, DRV: darunavir, RAL: raltegravir.
Table 2.
Characteristics of the 11 patients in whom new resistance-associated mutations (RAM) were detected during low-level viremia.